Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5JQ0D)

• Drug Name: Streptokinase Drug Info
• Synonyms: Awelysin; Estreptoquinasa; Kabikinase; Streptase; Streptochinasi; Streptokinasum; Streptochinasi [DCIT]; Streptococcal fibrinolysin; Estreptoquinasa [INN-Spanish]; Streptase (TN); Streptokinasum [INN-Latin]; 4-cyclohexylpyrrolidine-2-carboxylic Acid

Indication

Disease Entry	ICD 11	Status	REF
Pulmonary embolism	BB00	Approved	[1]
Acute myocardial infarction	BA41	Phase 4	[2]
Severe acute respiratory syndrome (SARS)	1D65	Discontinued in Phase 3	[3]

• Therapeutic Class: Thrombolytic Agents
• Cross-matching ID:
  PubChem CID: 9815560
  CAS Number: CAS 9002-01-1
  TTD Drug ID: DM5JQ0D

Molecule-Related Drug Atlas

Drug(s) Targeting Plasminogen (PLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[5]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[6]
Tranexamic Acid	DMFI8A7	Excessive bleeding	GA30.02	Approved	[7]
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[8]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[8]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[9]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[10]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[11]
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[12]
Plasminogen	DM0EFQS	Alzheimer disease	8A20	Phase 2/3	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Activator	[4]

References

• [1] Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
• [2] ClinicalTrials.gov (NCT00302419) Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT03465085) Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS. U.S. National Institutes of Health.
• [4] Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
• [5] Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
• [6] The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
• [7] Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
• [8] Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
• [9] Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
• [10] Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
• [11] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [12] Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
• [13] Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.